Grant: Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
University of British Columbia
$105,000.00
Development of oral child-friendly formulations for the maintenance therapy in childhood acute lymphoblastic leukemia
EF 2016-17
Résumé
Durable remissions in children with acute lymphoblastic leukemia (ALL) require a 2-to 3-year maintenance therapy that includes daily or weekly home administration of oral 6-mercaptopurine, methotrexate, and prednisone. The current clinical practice and available drug formulations are not truly child-friendly. As a result, medication adherence is poor, leading to an increased relapse rate. This project is aimed at developing child-friendly formulations for these drugs to improve medication adherence and ultimately, the therapeutic outcome for children suffering from ALL.
Programme
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
367821
Name
Tang Wei-Lun
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Development of oral child-friendly formulations for the maintenance therapy in childhood acute lymphoblastic leukemia
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Keyworddelim
Anticancer Drug Delivery; E-Tongue Technology; Lipid Nanoparticles; Oral Pediatric Formulation; Oro-Dispersible Formulation
Abstract
Durable remissions in children with acute lymphoblastic leukemia (ALL) require a 2-to 3-year maintenance therapy that includes daily or weekly home administration of oral 6-mercaptopurine, methotrexate, and prednisone. The current clinical practice and available drug formulations are not truly child-friendly. As a result, medication adherence is poor, leading to an increased relapse rate. This project is aimed at developing child-friendly formulations for these drugs to improve medication adherence and ultimately, the therapeutic outcome for children suffering from ALL.
Competitiondate
201610
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Tang, Wei-Lun
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~
